pharmaphorum5y
Sanofi settles dispute with Genzyme investors over MS drug
Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...
pharmaphorum12y
Sanofi’s Genzyme presents positive phase 3 data for MS drug
Genzyme, a subsidiary of Sanofi, has announced key data from its phase 3 clinical trials of its multiple sclerosis drug, Aubagio. The trials, called TOWER (Teriflunomide Oral in people With ...
Hosted on MSN11mon
Vanda stock jumps on $100M license deal for MS drug from J&J unit
The therapy has clinically shown to be superior to Aubagio, another approved drug for multiple sclerosis by Sanofi Genzyme (SNY). "The acquisition of Ponvory is a significant milestone for Vanda ...